Presentation First Quantum Imaging of Metabotropic Glutamate Receptor Subtype 1 in Parkinson’s Disease Rats Using A Novel PET Ligand [11C]ITDM

Yamasaki, Tomoteru  ,  Fujinaga, Masayuki  ,  Nagatsu, Kotaro  ,  Kawamura, Kazunori  ,  Ming-Rong, Zhang

2017-07-25
Description
Parkinson’s disease (PD) is a prevalent degenerative disorder affecting the central nervous system (CNS) that is primarily characterized by resting tremor and movement deficits. Metabotropic glutamate receptor subtype 1 (mGluR1) is an important target for investigation in several CNS disorders. In the present study, we investigated the in vivo role of mGluR1 in chronic PD pathology by performing longitudinal quantum imaging with positron emission tomography (PET) in PD model (PD-Tg) rats. PD-Tg rats showed a dramatic decline in general motor activities with age, along with abnormal ASN aggregation, and striatal neuron degeneration. In longitudinal PET imaging, striatal availability of [11C]ITDM, a selective PET ligand for mGluR1, temporarily increased prior to PD symptom onset, and dramatically decreased afterwards with age. Moreover, the dynamic changes in striatal availability of [11C]ITDM with mGluR1 also showed a high correlation in pathological decreases in general motor activities. Furthermore, declines in [11C]ITDM availability were correlated with decreases in availability of [18F]FE-PE2I, a specific PET ligand for the dopamine transporter, a biomarker for dopaminergic neurons. In conclusion, our results have demonstrated by the quantum imaging technology for the first time that dynamic changes occur in mGluR1, which accompany pathological progression in a PD animal model.
QST第1回国際シンポジウム『量子生命科学 -Quantum Life Science-』

Number of accesses :  

Other information